HOME >> BIOLOGY >> NEWS
Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)

Final media alert

Tuesday 16 March Saturday 20 March 2004
Congress Centrum, Am Dammtor, D-20355, Hamburg, Germany

EBCC-4 is the only forum in Europe that involves all the major players in breast cancer and is expected to attract a record 4,000 delegates from around 80 countries worldwide.

Provisional news briefing programme

Tuesday 16 March 13.00hrs
1. Professor Lars Holmberg: Why breast self-examination can be harmful
2. Dr Alane Koki: Breast cancer chip brings personalised treatment closer
3. Dr Lonneke van de Poll-Franse: Younger breast cancer survivors suffer more, even ten years later

Wednesday 17 March 13.00hrs
1. Dr Youlia Kirova: New findings BRCA genes and breast conservation is conservation treatment safe for carriers?
2. Dr Maartje Hooning: New findings from major study of breast cancer treatment and heart disease and intriguing indications that profile for breast cancer risk may protect against heart disease.
3. Dr Robert Paridaens: First results from international study of exemestane versus tamoxifen as first-line treatment in metastatic breast cancer

Thursday 18 March 13.00hrs
1. Dr Eric Winer: Rigorous testing needed for complementary and alternative therapies (CAMs) which CAMs are safe and which need further investigation?
2. Professor Dennis Holmes: New findings on DCIS and survival comparing conservation treatment and mastectomy

To find full details of the programme
Visit the EBCC-4 web site: http://www.fecs.be/conferences/ebcc4

Registration is free to all bona fide media on provision of press credentials

To register now: complete the attached form or register on the web site
http://www.fecs.be/conferences/ebcc4/media.shtml
OR: register on site as from Tuesday 16 March 2004.

If
'"/>

Contact: Stuart Bell
Stuart@fecs.be
322-775-0207
Federation of European Cancer Societies
19-Feb-2004


Page: 1 2

Related biology news :

1. Final Alert: 16th EORTC NCI AACR Symposium
2. Final of the 2003/04 Research Councils Business Plan Competition
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. L.A.Times Book Prize Finalist: Book On Evolution Of Bird Flight
5. Could A Nasal Vaccine Finally Get Rid Of The Black Death?
6. Last Comment Sought On Agents Proposed For Report On Carcinogens; A Final ForData On Saccharin, And A Re-Review Of Dioxin Announced
7. 2nd media alert First Scientific Conference on Childhood Leukaemia
8. American Chemical Society media registration
9. Chromatin remodeling may open up DNA to RNA-mediated silencing
10. Is genetic research hyped by the media?
11. Scientists beef up plant-dwelling bacteria to boost phytoremediation

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: